ClinicalTrials.gg
TerminatedNCT00718484PICASSOUpdated Oct 5, 2026

A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma

A Phase 2 interventional study of Palifosfamide-Tris and Doxorubicin in Soft Tissue Sarcoma, sponsored by Alaunos Therapeutics. Terminated at 23 sites in 3 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Alaunos Therapeutics · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor stopped enrollment at 67 of about 100 planned participants after an unplanned interim analysis confirmed the primary PFS endpoint had been reached. Enrolled participants were followed to their PFS endpoint.
Updated Oct 5, 2026Now TerminatedNow Completed+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 65 studies testing doxorubicin in Sarcoma — 13 open to participants now, 14 under way, 2 of them phase 3. Doxorubicin · Sarcoma.

Enrollment
21st of 60
67 · median 42
Started
2008
with 1 other
Phase 2
31 of 65
7 open now
Registered
33rd of 65
by date

Among the 65 studies testing doxorubicin in Sarcoma, this one is the 21st largest by enrollment of the 60 interventional ones that give a count, is one of 2 that started in 2008, is one of 31 in phase 2, and was the 33rd registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

13 of the 65 studies testing doxorubicin in Sarcoma are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About doxorubicin

Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing doxorubicin in Sarcoma, or all of them as a file.
02

Study summary

This is a randomized, controlled trial to evaluate the clinical benefit of palifosfamide tris administered with doxorubicin in combination, compared with single-agent doxorubicin administered in subjects diagnosed with unresectable or metastatic soft-tissue sarcoma (STS). Subjects who meet the entry criteria will be randomized into 1 of 2 arms: either to receive palifosfamide tris plus doxorubicin or treatment with single-agent doxorubicin. Subjects will be anthracyclin naïve.

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

Keywords

  • Sarcoma
  • Soft Tissue Sarcoma
  • Doxorubicin
  • anthracyclin
  • Palifosfamide
  • IFOS
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Histological or cytological documentation of sarcoma (excluding alveolar soft-part sarcoma, chondrosarcoma, dermatofibrosarcoma, Ewing sarcoma, GIST, Kaposi sarcoma, mixed mesodermal tumor, osteosarcoma, radiation induced sarcomas, and unresectable low grade liposarcoma) who have failed ≤2 prior regimens including therapy, or ≤1 prior regimen for /unresectable disease, and for whom treatment with doxorubicin is considered medically acceptable. Prior treatment with IFOS is acceptable.
  3. Have as per criteria (Appendix 2)
  4. Performance Status of 0 or 1 (Appendix 3)
  5. Anthracyclin naïve
  6. of ≥12 weeks
  7. Adequate bone marrow, liver, and renal function, as assessed by the following laboratory requirements conducted within 14 days prior to dosing:

    1. ≥9.0 g/dL
    2. (ANC) ≥1,500/mm3
    3. count 100,000/mm3
    4. Total ≤1.5× (upper limit of normal)
    5. and AST ≤2.5×ULN or 5×ULN with hepatic disease
    6. Partial thromboplastin [PT]-/activated partial thromboplastin time [PTT] \<1.5×ULN (≤2.0×ULN for subjects on anticoagulation prophylactic regimen). Subjects who are being therapeutically anticoagulated with an agent such as Coumadin (warfarin sodium) or heparin are allowed provided there is no prior evidence of underlying abnormality in coagulation parameters. If an interaction between study drug and anticoagulant is suspected, anticoagulation monitoring should be increased as appropriate.
    7. Serum creatinine ≤ULN
  8. Written must be obtained from a potential subject prior to the conduct of any study-specific procedures
  9. Male and female subjects must agree to use adequate measures/barrier control during the course of the trial
  10. Women of must have a urine pregnancy test performed within 14 days of the start of treatment

Exclusion criteria

Exclusion Criteria:

  1. Has any one of the following sarcoma sub types: alveolar soft-part sarcoma, chondrosarcoma, dermatofibrosarcoma, Ewing sarcoma, GIST, Kaposi sarcoma, mixed mesodermal tumor, osteosarcoma, radiation induced sarcomas, and unresectable low grade liposarcoma.
  2. Clinically evident congestive heart failure >Class II of the (NYHA) guidelines (Appendix 4)
  3. Serious, cardiac arrhythmias, defined as the existence of an absolute arrhythmia, or ventricular arrhythmias classified as Lown III, IV, or V (Appendix 4)
  4. History and/or signs of active coronary artery disease/ischemia with or without angina pectoris
  5. Serious myocardial dysfunction defined as scintigraphically ( [multiple gated acquisition scan], myocardial scintigram) or ultrasound-determined absolute left ventricular ejection fraction (LVEF) \<45%
  6. History of infection
  7. Prior nephrectomy or history of urinary tract obstruction
  8. Active, clinically serious infection requiring systemic antibacterial, antifungal, or antiviral therapy
  9. Any major surgery within 3 weeks prior to start of treatment
  10. brain or meningeal tumors, unless the subject is >6 months from definitive therapy and has a negative imaging study within 4 weeks of study entry. In addition, the subject must not be undergoing acute therapy or taper (chronic steroid therapy is acceptable, provided the dose is stable for 1 month prior to study start, and following screening radiographic studies).
  11. Previous (except cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumors [Ta, Tis, \& T1] or other malignancies curatively treated >5 years prior to entry)
  12. Pregnancy or lactation
  13. Substance abuse or medical, psychological, or social conditions that may interfere with the subject's participation in the study or evaluation of the study results
  14. Any condition that is unstable or could jeopardize the safety of a subject and his/her compliance with the protocol requirements

    In addition, use of the following therapies and medications-prior or concomitant-would exclude a subject from this study:

  15. Anticancer chemotherapy, immunotherapy, or any drug therapy during the study or within 4 weeks of study entry (6 weeks for Mitomycin C)
  16. Prior treatment with doxorubicin
  17. Radiotherapy within 4 weeks of study entry (palliative radiation to bone lesions is permitted if started or planned prior to Cycle 1, Day 1)
  18. Bone marrow transplant or stem cell rescue within 4 months of study entry
  19. Growth factors such as G-CSF (granulocyte colony-stimulating factor/filgrastim), or biological response modifiers within 3 weeks of study entry
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Palifosfamide-Tris Plus Doxorubicin

    Participants received palifosfamide-tris 150 mg/m² IV on Days 1, 2, and 3 plus doxorubicin 75 mg/m² IV on Day 1 of each 21-day cycle for up to 6 cycles. Doxorubicin was administered approximately 60 minutes after completion of the Day 1 palifosfamide-tris infusion. Participants could continue single-agent palifosfamide-tris after completion of combination treatment.

    Drug: Palifosfamide-Tris · Drug: Doxorubicin

  • Active comparator
    Doxorubicin Alone With Optional Palifosfamide-Tris After Progression

    Participants received doxorubicin 75 mg/m² IV on Day 1 of each 21-day cycle for up to 6 cycles. Participants whose disease progressed at or before Cycle 6 could elect to receive single-agent palifosfamide-tris after disease progression. This treatment was optional and was not part of the randomized initial treatment assignment.

    Drug: Palifosfamide-Tris · Drug: Doxorubicin

Interventions

  • DrugIsophosphamide mustardStudies of Isophosphamide mustardIsophosphamide mustard pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Palifosfamide-tris 150 mg/m² administered intravenously on Days 1, 2, and 3 of each 21-day cycle.

    Also known as: ZIO-201, isophosphoramide mustard

  • Doxorubicin 75 mg/m² administered intravenously on Day 1 of each 21-day cycle for up to 6 cycles.

    Also known as: Adriamycin

06

What researchers measure

Primary outcomes

  1. The primary efficacy analysis will be conducted on the intent-to-treat (ITT) population. All attempts will be made to conduct assessment of disease status every 6 weeks until progression of disease or initiating off protocol anti cancer therapies.

    Time frame: Every 6 weeks until progression

07

Study locations

23 sites
  • Santa Monica, California, United States
  • Washington D.C., District of Columbia, United States
  • Tampa, Florida, United States
  • Coeur d'Alene, Idaho 83814, United States
  • Chicago, Illinois, United States
  • Park Ridge, Illinois, United States
  • Iowa City, Iowa, United States
  • Lenexa, Kansas, United States
  • Albuquerque, New Mexico, United States
  • New York, New York, United States
  • Durham, North Carolina, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Memphis, Tennessee, United States
  • Nashville, Tennessee, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Seattle, Washington, United States
  • Milan, Italy
  • Padova, Italy
  • Torino, Italy
  • Cluj-Napoca, 400015, Romania
  • Lasi, Romania
08

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2008 to primary completion in Sep 2010, 24 months.

Start moved once since we started tracking on Sep 25, 2026: Aug 2008 → Sep 2008, on Sep 29, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Apr 2012 → Sep 2010, on Sep 29, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Apr 2014 → Sep 2010, last on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2008
First posted
Jul 18, 2008
StartActual
Sep 3, 2008was Aug 2008
Primary completionActual
Sep 20, 2010was Apr 2012
CompletionActual
Sep 20, 2010was Apr 2014
Results delay requested
Sep 28, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed→Terminated Sponsor stopped enrollment at 67 of about 100 planned participants after an unplanned interim analysis confirmed the primary PFS endpoint had been reached. Enrolled participants were followed to their PFS endpoint.
changed Sep 29, 2026 · changed Sep 30, 2026
Sites
3 sites added, 3 sites removed
Show 3 added (3 United States)
  • Washington D.C. · Washington D.C., United States
  • Iowa City · Iowa City, United States
  • Lenexa · Lenexa, United States
Show 3 removed
  • Washington · Washington, United States
  • Iowa city · Iowa city, United States
  • Lenaxa · Lenaxa, United States
Sep 29, 2026
Start date
Aug 2008→Sep 3, 2008 (actual)
Sep 29, 2026
Primary completion
Apr 2012→Sep 20, 2010
Sep 29, 2026
Study completion
Apr 2014→Sep 20, 2010
moved 2 times, Sep 29, 2026 – Sep 30, 2026
Eligibility
Maximum age none→120 Years
Sep 29, 2026
Interventions
Changed Palifosfamide Tris and Doxorubicin→Palifosfamide-Tris. Arms added: Palifosfamide-Tris Plus Doxorubicin·Doxorubicin Alone With Optional Palifosfamide-Tris After Progression; arms removed: A·B
across 2 updates, Oct 1, 2026 – Oct 5, 2026
Show all 4 updates
  1. Oct 5, 2026
    Interventions Arms added: Palifosfamide-Tris Plus Doxorubicin·Doxorubicin Alone With Optional Palifosfamide-Tris After Progression; arms removed: A·B
    + 1 other change: verification date
  2. Oct 1, 2026
    Interventions Changed Palifosfamide Tris and Doxorubicin→Palifosfamide-Tris
    + 2 other changes: index terms and design details
  3. Sep 30, 2026
    Completed→Terminated
    Why stopped Sponsor stopped enrollment at 67 of about 100 planned participants after an unplanned interim analysis confirmed the primary PFS endpoint had been reached. Enrolled participants were followed to their PFS endpoint.
    Study completion Sep 20, 2011→Sep 20, 2010
  4. Sep 29, 2026
    Status unknown→Completed
    3 sites added, 3 sites removed
    Show 3 added (3 United States)
    • Washington D.C. · Washington D.C., United States
    • Iowa City · Iowa City, United States
    • Lenexa · Lenexa, United States
    Show 3 removed
    • Washington · Washington, United States
    • Iowa city · Iowa city, United States
    • Lenaxa · Lenaxa, United States
    Start date Aug 2008→Sep 3, 2008 (now actual)
    Primary completion Apr 2012→Sep 20, 2010
    Study completion Apr 2014→Sep 20, 2011 (now actual)
    Eligibility Maximum age none→120 Years
    + 3 other changes: index terms, verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT00718484
Responsible party
Sponsor
First posted
Jul 18, 2008
Start date
Sep 3, 2008
Primary completion
Sep 20, 2010
Completion
Sep 20, 2010
Last update
Oct 5, 2026

Study contacts

Jonathan J Lewis, MD, PhD
study director · ZIOPHARM Oncology, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Isophosphamide mustard · Doxorubicin

Start the discussion